Authors: EMJ
Support: The publication of this content was supported by Bristol Myers Squibb.
Citation: Neurol AMJ. 2024;1[1]. https://doi.org/10.33590/neurolamj/TGYV1519.
Original citation: Neurol AMJ. 2024;1[1]:64-65. https://doi.org/10.33590/neurolamj/IYAW3561.
Date correction published: 14.06.2024
In the infographic1 published under AMJ Neurology, on 30th May 2024, the graphs depicting safety over time titled ‘Malignancy TEAEs’ and ‘Hepatic TEAEs’ are labelled ‘Malignancy Infection’ and ‘Hepatic Infection’, respectively. This is incorrect and these labels have now been rectified to read ‘Malignancy TEAE’ and ‘Hepatic TEAE’, referring to treatment emergent adverse events.
EMJ apologises for the error and any inconvenience caused by the incorrect labelling of these graphs.
Reference:
1. European Medical Journal (EMJ). Ozanimod long-term safety and efficacy results from the completed DAYBREAK extension trial. AMJ Neurology. 2024;1(1):64-5.
